Refine
Document Type
- Article (9)
- Doctoral Thesis (1)
Language
- English (10)
Has Fulltext
- yes (10)
Is part of the Bibliography
- no (10)
Keywords
- - (9)
- metabolomics (4)
- metabolome (2)
- 3,5-Diiodothyronine (1)
- 3,5-diiodothyronine (1)
- Diabetes mellitus (1)
- Epidemiologie (1)
- Formula diet (1)
- Hyperthyreose (1)
- Individualization (1)
- Medical treatment (1)
- Metabolomics (1)
- NMR spectroscopy (1)
- Obesity (1)
- Quality of life (1)
- Schilddrüse (1)
- Thyroid hormone (1)
- Thyroxin (1)
- Trigonelline (1)
- Urine metabolome (1)
- anti-steatotic action (1)
- apparently healthy (1)
- bacteria (1)
- biomarkers (1)
- blood cell metabolism (1)
- chemoluminescence immunoassay (1)
- coffee metabolites (1)
- complete blood count (1)
- cortisol (1)
- deiodinase (1)
- directed acyclic graphs (1)
- exercise (1)
- heart failure with preserved ejection fraction (1)
- hypothyroidism (1)
- individualized medicine (1)
- inflammation (1)
- iron surrogates (1)
- lipoprotein profiling (1)
- measurement error (1)
- mediation (1)
- metabolism (1)
- obesity (1)
- oral contraceptives (1)
- periodontitis (1)
- personalized medicine (1)
- population‐based study (1)
- prediction modelling (1)
- thyroid hormone (1)
Institute
Publisher
- MDPI (3)
- S. Karger AG (2)
- SAGE Publications (2)
- Frontiers Media S.A. (1)
- Wiley (1)
Introduction: Patients who are overweight or obese have an increased risk of developing type 2 diabetes mellitus (T2DM). Weight loss can have a positive effect on glycemic control. Objective: We aimed to investigate glycemic control in patients with T2DM and overweight or obesity during a structured weight-loss program. Methods: This was a prospective, interventional study. We recruited 36 patients (14 men and 22 women) with a median age of 58.5 years and median body mass index (BMI) of 34.1, to a 15-week structured weight-loss program with a low-calorie (800 kcal) formula diet for 6 weeks. The primary end point, HbA<sub>1c</sub> level, and secondary end points, anthropometric data, medication, and safety, were assessed weekly. Laboratory values and quality of life were assessed at baseline and after 15 weeks. Results: HbA<sub>1c</sub> decreased from 7.3% at baseline to 6.5% at 15 weeks (p < 0.001), median body weight by 11.9 kg (p < 0.001), median BMI by 4.3 (p < 0.001) and median waist circumference by 11.0 cm (p < 0.001). Two participants discontinued insulin therapy, 4 could reduce their dosage of oral antidiabetic agents, and 6 completely discontinued their antidiabetic medication. Insulin dose decreased from 0.63 (0.38–0.89) to 0.39 (0.15–0.70) units/kg body weight (p < 0.001). No patient experienced hypoglycemic episodes or hospital emergency visits. Triglycerides and total cholesterol decreased as well as surrogate markers of liver function. However, the levels of high-density and low-density lipoprotein cholesterol (HDL-C and LDL-C) as well as uric acid remain unchanged. Regarding quality of life, the median physical health score increased from 44.5 (39.7–51.4) at baseline to 48.0 (43.1–55.3; p = 0.007), and the median mental health score decreased from 42.1 (36.1–46.7) to 37.4 (30.3–43.7; p = 0.004). Conclusions: A structured weight-loss program is effective in the short term in reducing HbA<sub>1c</sub>, weight, and antidiabetic medication in patients with T2DM who are overweight or obese. Levels of HDL-C and LDL-C were not affected by short-term weight loss. The decline in mental health and the long-term effects of improved glycemic control require further trials.